Compare Merck & Co., Inc. (MRK) vs AT&T Inc. (T) Price & Performance

Merck & Co., Inc.Trade

AT&T Inc.Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs AT&T Inc. — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while AT&T Inc. trades at $22.3 (market cap $152.52B). The key difference: Merck & Co., Inc. is far larger — about 2× AT&T Inc.'s market cap, and AT&T Inc. pays the higher dividend (5.06%). Which is the better fit depends on your goals.

	MRK	T
Market Cap	$307.25B	$152.52B
Sector	Health	Media
52-Week High	$129.52	$29.62
52-Week Low	$77.60	$20.49
Enterprise Value	$350.66B	$297.87B
Dividend Yield	2.73%	5.06%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

AT&T Inc.

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

Wall Street braces for volatility as Big Tech earnings and AI updates dominate this week.Proactive Investors · 1 day agoNeutral Vanguard High Dividend Yield ETF offers durable income with strong dividend coverage and steady returns.24/7 Wall Street · 4 days agoBullish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About AT&T Inc.

AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.